Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

The US Food and Drug Administration (FDA) has approved Merck &Co’s Keytruda plus Roche’s Herceptin and chemotherapy in the first-line setting for HER2-positive advanced gastric or gastroesophageal ... From the start of Keytruda’s development, we

Latest news

More from news
Approximately 6 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as adjuvant (post-surgery) trial results later this year and in 2021. ... If successful, that would dramatically increase the eligible patient

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....